Avastin News and Research

RSS

Avastin is a biologic antibody designed to specifically bind to a protein called vascular endothelial growth factor (VEGF) that plays an important role throughout the lifecycle of the tumor to develop and maintain blood vessels, a process known as angiogenesis. Avastin is designed to interfere with the blood supply to a tumor by directly binding to the VEGF protein to prevent interactions with receptors on blood vessel cells. Avastin does not bind to receptors on normal or cancer cells. The tumor blood supply is thought to be critical to a tumor’s ability to grow and spread in the body (metastasize).

A view on new drugs for macular degeneration

Restricting use of drugs for macular degeneration to patients who have already gone blind in one eye is "unacceptable" concludes the July issue of Drug and Therapeutics Bulletin (DTB).

4 Jul 2007

Avastin helps those with radiation retinopathy

Patients with radiation retinopathy who were destined to go blind within five years now can keep their sight longer through localized treatment with Avastin, a well-known cancer drug, according to a two-year study published in the June, 2007 Archives of Ophthalmology.

23 Jun 2007

Britain second rate when it comes to treating cancer sufferers

When it comes to accessing the best drugs for cancer Britain is a second rate country to be sick in.

14 May 2007

Novel therapies to prevent metastasis

In a study that could point to novel therapies to prevent cancer spread, or metastasis, researchers at the University of California, San Diego (UCSD) School of Medicine have targeted a sugar that supports blood vessel growth in the tumor.

8 May 2007

Developing world can expect a 'pandemic of cancer' by 2020

The developing world is expected to account for more than half of all cancer cases in the world by 2020 say medical experts.

23 Apr 2007

Peregrine's selective anti-VEGF antibodies shown to be as effective as Avastin

Peregrine Pharmaceuticals has reported that preclinical data presented at the Centennial Annual Meeting of the American Association for Cancer Research (AACR) showed that its monoclonal antibody 2C3, which selectively blocks vascular endothelial growth factor (VEGF) from binding to the second of the two VEGF receptors, demonstrates potent anti-cancer efficacy in a preclinical orthotopic model of pancreatic cancer.

17 Apr 2007

Targeted therapies improve colon cancer survival rates

People diagnosed with advanced colorectal cancer that has spread to distant organs, such as White House spokesman Tony Snow, are much more likely to survive today than even just a few years ago, due to the recent and continued emergence of improved therapies, say cancer experts.

3 Apr 2007

Avastin slows growth of gliomas

Avastin, a relatively new type of drug that shrinks cancerous tumors by cutting off their blood supply, can slow the growth of the most common and deadly form of brain cancer, a pilot study conducted at Duke University Medical Center has found.

20 Feb 2007

Bionomics delivers on milestones for cancer, anxiety and multiple sclerosis programs

Australian drug discovery company Bionomics Limited today updated shareholders at its Annual General Meeting on the recent progress of its anti-cancer drug BNC105 and drug discovery programs in anxiety and Multiple Sclerosis.

8 Nov 2006

National Eye Institute to finance two-year study comparing effectiveness of treatments for macular degeneration

The National Eye Institute on Thursday said it will finance a two-year study comparing the effectiveness of Genentech's eye treatment Lucentis and cancer drug Avastin for treating wet age-related macular degeneration, the New York Times reports.

8 Oct 2006

FDA more cautious in approving new drugs after Vioxx

Many pharmaceutical companies and industry observers say that FDA is "quietly becoming more assertive about keeping new drugs off the market or refusing to approve new uses for existing medications" in response to criticism since the 2004 Vioxx recall, the New York Times reports.

3 Oct 2006

Brits denied new targeted bowel cancer drugs

Despite the fact that bowel cancer is the third most common form of the disease in Britain and kills 16,000 people every year, the government watchdog on drugs the National Institute for Health and Clinical Excellence (NICE) has sparked a bitter controversy by refusing to provide two bowel cancer drugs on the National Health Service (NHS) to cancer patients.

21 Aug 2006

Cancer stem cells spur glioma angiogenesis, could hold key to brain tumor therapy

Stem cell-like glioma cancer cells that share many characteristics with normal stem cells propel the lethal growth of brain cancers by promoting tumor blood vessel formation, and may hold the key to treating these deadly cancers.

15 Aug 2006

Sunitinib malate shows promise against advanced form of lung cancer

Results of a multi-center clinical study of a drug currently approved for treatment of kidney cancer indicate that it may also be effective for people with recurrent and advanced lung cancer.

5 Jun 2006

Most cancer victims unaware of anti-angiogenesis

According to a new survey nine out of ten patients battling cancer in Europe have never heard of the major breakthrough in cancer treatment, known as anti-angiogenesis.

From The University of Manchester 28 Mar 2006

Trial of paclitaxel with or without bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer

Results from a large, randomised clinical trial for patients with breast cancer show that those who received bevacizumab (Avastin.) in combination with paclitaxel (Taxol.) survived without the disease getting worse for almost twice as long as patients who received paclitaxel alone.

23 Mar 2006

Avastin trial for pancreatic tumors

"Our findings from the previous study suggest that the combination of chemotherapy and radiation is a safe and effective treatment method to reduce the local extent of pancreatic tumors," said Dr. Talamonti.

23 Feb 2006

Hopes dashed for peanut allergy drug Xolair

Hopes have been dashed for a potential treatment for peanut allergies following the severe reactions suffered by two children during a clinical trial.

18 Jan 2006

Targeted cancer therapies: Another step forward

While it is clear that the treatment of cancer has already begun to undergo a paradigm shift with the inclusion of innovative targeted therapies into current regimens, it would be wrong to assume these products will entirely replace traditional chemotherapy as the standard treatment for cancer sufferers.

22 Dec 2005